This article, written by Sidhesh Phaldessai, provides an overview of geriatric psychopharmacology, including the epidemiology of mental health disorders in the older population, the physiological changes that occur with ageing and their impact on pharmacokinetics and pharmacodynamics, and the use of psychotropic medications in older adults
AFT submits Maxigesic IV® packaging data to the US FDA
AFT submits Maxigesic IV® packaging data to the US FDA
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has submitted to the US
Food and Drug Administration (FDA) data the regulator requested as it considers
registration of the company’s patented intravenous pain relief medicine Maxigesic IV.
In a delay to the registration of the medicine in the US, the FDA requested in July 2022
additional data on the performance of Maxigesic IV’s primary packaging (the glass
vial in which the medicine is stored and the vial’s stopper).
AFT along with its commercialisation partner Belgium’s Hyloris Pharmaceuticals has
over the last year collated the data and submitted today.
AFT Managing Director Dr Hartley Atkinson said: “We believe the data we have
submitted will satisfy the FDA’s requirements and remove the outstanding hurdle to
registration. All going well we anticipate registration of the medicine this year and
sales to follow shortly after.”
Maxigesic IV, is a novel, unique combination of 1000mg paracetamol and 300mg
ibuprofen solution for infusion, for the treatment of post-operative pain. It has been
developed in collaboration with Hyloris and is currently licensed in more than 100
countries across the globe. It has also been registered in 43 countries and launched
in 19 countries including Australia, France, Germany, and Korea. The medicine is
protected by several granted patents and pending patent applications.